Moreover, the inhibition of miR-587 or restoration of PPP2R1B expression may have significant therapeutic potential for overcoming drug resistance in CRC patients, and the combined use of an AKT inhibitor with 5-FU may increase the efficacy of CRC treatment [25]. Here, AKT1 is linked to colorectal carcinoma.